-
-
-
-
-
-
-
Kura Oncology (KURA) Reiterated at Market Outperform by Citizens
-
-
-
-
-
-
-
Kura Oncology reports darlifarnib plus cabozantinib shows activity in kidney cancer
-
-
-
-
-
-
-
Kura Oncology reports $2.1 million in KOMZIFTI revenue for first weeks
-
-
-
-
-
-
-
Kura Oncology (KURA) PT Raised to $25 at Leerink Partners
-
-
-
-
-
-
-
Kura Oncology receives $30 million milestone from Kyowa Kirin partnership
-
-
-
-
-
-
-
Kura Oncology publishes ziftomenib trial data in oncology journal
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Kura Oncology (KURA)
-
446,727 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

